Award

Finding Alzheimer’s disease progression markers

Description: Project summary: Alzheimer’s disease has a long predementia phase that starts with the aggregation of amyloid beta into plaques when cognition is still intact. It can then take up to 15 years for dementia to start. This provides a window of opportunity to slow down or even prevent dementia. However, individuals vary greatly in terms of cognitive decline and the underlying mechanisms related to disease progression remain largely unknown. We recently discovered five AD subtypes based on cerebrospinal fluid (CSF) proteomics that were characterized by distinct molecular processes: one with hyperplasticity, one with innate immune dysfunction, one with dysregulated RNA metabolism, one with choroid plexus dysfunction and one with blood-brain barrier impairment. These subtypes were already apparent in the predementia stage of AD, and subtypes differed in rates of cognitive decline and survival times. This leads us to hypothesize that different molecular mechanisms may explain differences in disease progression in AD. Testing this hypothesis requires a large sample of individuals with long-term clinical follow up, repeated CSF sampling, cognitive testing, and genetics, which does not exist yet and we will create in this consortium. Teaser: Alzheimer’s disease has a long predementia phase that starts with the aggregation of amyloid beta into plaques when cognition is still intact. It can then take up to 15 years for dementia to start. This provides a window of opportunity to slow down or even prevent dementia. However, individuals v... Disciplines: [["Medisin og helsefag", "Klinisk medisinske fag", "Nevrologi"]] Geographies: [["Oslo - Oslove", "Oslo - Oslove"]]
Amount: NOK 2,000,000
Funding type: research
Funder scheme: HELSEFORSKNING-Helseforskning
Start date: 2025-01-01
End date: 2028-12-31
Investigator: Tormod Fladby
Institution: UNIVERSITETET I OSLO
Funded outputs count: 0
Funder award ID: rcn-foriss-360614
OpenAlex ID: G8409698256
Year
Topic